Prescription drugs in the United States cost roughly three times what they cost in other wealthy nations. Even after accounting for rebates and discounts, brand-name drugs are at least 3.22 times as expensive in the U.S. as in comparable countries. There’s no single villain behind this markup. Instead, several interlocking forces push prices up and keep them there.
No Government Price Controls
Most developed countries negotiate drug prices at a national level, setting caps on what manufacturers can charge. The U.S. has historically left pricing almost entirely to the market. Manufacturers set their own list prices, and until very recently, even Medicare, the largest single buyer of prescription drugs in the country, was legally prohibited from negotiating prices directly with drugmakers.
That changed partially with the Inflation Reduction Act. Starting January 1, 2026, Medicare will pay negotiated prices on 10 high-spend drugs, including blood thinners like Eliquis and Xarelto, diabetes medications like Jardiance and Januvia, and the autoimmune drug Stelara. But this covers a tiny fraction of the thousands of drugs on the market, and it applies only to Medicare, not to the broader commercially insured population. For most Americans, the price of a brand-name drug is still whatever the manufacturer decides to charge.
The Rebate System That Rewards Higher Prices
Between a drugmaker and your pharmacy sits a powerful middleman: the pharmacy benefit manager, or PBM. PBMs negotiate rebates from manufacturers on behalf of insurers and large employers. In theory, this should push prices down. In practice, it often does the opposite.
Three companies handle roughly 60% of the PBM market: CVS Health, OptumRx, and Express Scripts. Because losing access to even one of these giants means losing a huge share of patients, manufacturers are under intense pressure to offer large rebates to stay on preferred drug lists. The catch is that rebates are calculated as a percentage of the list price. So manufacturers raise the list price to absorb the rebate and still protect their margins. Research from the USC Schaeffer Center found that for every $1 increase in rebates, the list price of a drug rises by $1.17. The rebate system, in other words, creates a financial incentive to inflate the sticker price.
Who gets hurt? Patients with high-deductible plans or no insurance at all. They often pay based on the list price, not the discounted price the insurer actually negotiated. The rebate dollars flow between PBMs and insurers, not to the person standing at the pharmacy counter.
The Cost of Development and Failure
Bringing a new drug to market is genuinely expensive, and manufacturers point to these costs to justify high prices. The out-of-pocket cost of developing a single drug averages around $173 million. But that number doesn’t tell the whole story, because most drug candidates fail. When you factor in the cost of all the drugs that never made it through clinical trials, plus the capital tied up during years of development, the effective cost per successful drug climbs to roughly $879 million.
Drugmakers have also been spending more on research over time. R&D spending across the industry grew tenfold between 1979 and 2018, reaching $61.1 billion. As a share of sales revenue, R&D climbed from about 5% to 19% over that same period. These are real costs that need to be recouped, and companies typically have a limited window of patent exclusivity to do it before generics enter the market.
That said, high development costs don’t fully explain why the same drug sells for three times more in the U.S. than in France or Canada. Development costs are global, but the pricing gap is uniquely American. Companies charge more in the U.S. in part because they can, recovering a disproportionate share of their global R&D investment from American patients and insurers.
Marketing Adds to the Tab
The United States is one of only two countries (New Zealand is the other) that allows pharmaceutical companies to advertise prescription drugs directly to consumers. Drug manufacturers spent about $6 billion per year on direct-to-consumer advertising between 2016 and 2018, covering television spots, magazine ads, and digital campaigns for over 550 drugs.
A common claim is that drugmakers spend more on marketing than research. The data doesn’t support that. Advertising accounted for about 3% of sales revenue in 2018, compared to 19% for R&D. Still, $6 billion a year in consumer advertising is a significant expense, and it shapes prescribing patterns. When patients ask for a brand-name drug they saw on TV, they’re less likely to end up on a cheaper alternative that works just as well. That advertising spend gets baked into the price of the drug.
Patent Protection and Limited Generic Competition
Brand-name drugs are protected by patents that typically give the manufacturer years of market exclusivity. During this window, there’s no generic alternative, and the company faces little competitive pressure on price. Manufacturers sometimes extend this window through strategies like filing additional patents on new formulations or delivery methods of the same drug.
When generics do arrive, prices drop significantly, but the size of the drop depends entirely on how many competitors enter the market. With about three generic competitors, prices fall roughly 20%. With ten or more, prices can fall 70% to 80% below the original brand-name price. The problem is that many drugs, especially those for rare diseases or complex conditions, attract only one or two generic manufacturers. In those cases, the price barely budges.
For a drug with only one generic competitor, patients might still pay 75% to 85% of the original brand-name price. It’s only when ten or more companies are making the same generic that the price drops to around 20% of the brand-name cost. Markets with fewer patients or more complicated manufacturing processes simply don’t attract enough competitors to drive prices down.
What This Costs Patients
High prices have real consequences at the pharmacy. Among Americans 65 and older, about 3.6% report skipping a prescription entirely because of cost, and a similar share say they don’t take their medications as prescribed to save money. Some delay filling prescriptions, others cut pills in half or skip doses. These numbers may sound small in percentage terms, but applied to the tens of millions of older adults in the U.S., they represent millions of people rationing medication for chronic conditions like diabetes, heart disease, and arthritis.
The cost burden falls unevenly. People without insurance pay the full list price. Those with high-deductible health plans may pay close to list price until they hit their deductible, which can take months. Even insured patients with copays tied to a percentage of the drug’s cost (coinsurance) can face bills of hundreds or thousands of dollars per month for specialty medications. The system essentially asks American patients to subsidize drug development for the rest of the world while navigating a pricing structure designed around negotiations they never see and discounts they never receive.